Controversies in small vessel vasculitis - Comparing the rheumatology and nephrology views

Current Opinion in Rheumatology

Volumn 19, Issue 1, 2007, Pages 1-9

  Falk, Ronald J ^a   Hoffman, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; SURFACTANT;

ANTIBODY PRODUCTION; BONE MARROW DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG USE; EXCHANGE BLOOD TRANSFUSION; HEMOCYTOPENIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; MAINTENANCE THERAPY; MEDICAL SPECIALIST; MICROSCOPIC POLYANGIITIS; NEPHROLOGY; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOLOGY; RISK FACTOR; SMALL VESSEL VASCULITIS; TREATMENT DURATION; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; HUMANS; NEPHROLOGY; RHEUMATOLOGY; TERMINOLOGY; VASCULITIS;

EID: 33845363822     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328011cb80     Document Type: Review

References (35)

1. Stone JH. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2003; 48:2299-2309.
2. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.
3. Birck R, Schmitt WH, Kaelsch IA, Van Der Woude FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006; 47:15-23.
4. Finkielman JD, Merkel PA, Schroeder D, et al., for the WGET Research Group. Antineutrophil cytoplasmic antibodies against proteinase 3 do not predict disease relapses in Wegener's granulomatosis [abstract]. Arthritis Rheum 2006; 54 (Suppl):835-836.
5. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004; 93:398-401.
6. Schlieben DJ, Korbet SM, Kimura RE, et al. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 2005; 45:758-761.
7. Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632-638.
8. Sinico RA, Di TL, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52:2926-2935.
9. Godman GC, Churg J. Wegener's granulomatosis. Pathology and review of the literature. Arch Pathol Lab Med 1954; 58:533-553.
10. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187-192.
11. Wegener's Granulomatosis Etanercept Trial Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361.
12. Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143:621-631.
13. Jennette JC, Falk RJ. Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. Nephrol Dial Transplant 1998; 13 (Suppl 1):16-20.
14. Day CJ, Hewins P, Savage CO. New developments in the pathogenesis of ANCA-associated vasculitis. Clin Exp Rheumatol 2003; 21:S35-S48.
15. Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by antineutrophil cytoplasmic antibodies. J Am Soc Nephrol 2006; 17:1235-1242.
16. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955-963.
17. Little MA, Smyth CL, Yadav R, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005; 106:2050-2058.
18. Xiao H, Heeringa P, Liu Z, et al. The role of neutrophils in the induction of glomerulonephritis by antimyeloperoxidase antibodies. Am J Pathol 2005; 167:39-45.
19. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004; 51:269-273.
20. Kyndt X, Reumaux D, Bridoux F, et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999; 106:527-533.
21. Keogh KA, Specks U. Churg-Strauss syndrome: update on clinical, laboratory and therapeutic aspects. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:3-12.
22. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461-2469.
23. De Groot K, Jayne DR, Tesar V, Savage CO. European, multicenter randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis for the European Vasculitis Study Group [abstract]. J Am Soc Nephrol 2005; 16:7A.
24. Gaskin G, Jayne DR, European Vasculitis Study Group. Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis. J Am Soc Nephrol 2002; 13:2A-3A.
25. Langford CA, Talar W, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43:1836-1840.
26. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992; 35:1322-1329.
27. Sneller MC, Hoffman GS, Talar-Williams C, et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38:608-613.
28. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114:463-469.
29. Hoffman GS. Treatment of Wegener's granulomatosis: time to change the standard of care? Arthritis Rheum 1997; 40:2099-2104.
30. Villa-Forte A, Clark TM, Mascha E, et al. Wegener granulomatosis: customized treatment using cyclophosphamide and methotrexate [abstract]. Arthritis Rheum 2006; 54 (Suppl):495.
31. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of antiglomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 134:1033-1042.
32. Hogan SL, Nachman PH, Wilkman AS, et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7:23-32.
33. Klemmer PJ, Chalermskulrat W, Reif MS, et al. Treatment with plasmaphersis in diffuse alveolar hemorrhage in ANCA-SVV [abstract]. Clin Exp Immunol 2000; 120:73.
34. Falk RJ, Hogan SL, Muller KE, Jennette JC. Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann Intern Med 1992; 116:438-445.
35. De Groot K, Jayne D. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. Clin Nephrol 2005; 64:480-484.